Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)

Ronan T. Swords, Peter L. Greenberg, Andrew H. Wei, Simon Durrant, Anjali S. Advani, Mark S. Hertzberg, Ian D Lewis, Gabriel Rivera, Dita Gratzinger, Alice C. Fan, Dean W. Felsher, Jorge E. Cortes, Justin M. Watts, Geoff T. Yarranton, Jackie M. Walling, Jeffrey E. Lancet

Research output: Contribution to journalComment / DebateOtherpeer-review

Abstract

The authors regret to inform, that a key author (Dr. Brian A. Jonas MD PhD), was inadvertently omitted form the authorship of this manuscript at the time of publication. Dr. Jonas was a key contributor to the design, conception and data analysis of this work. He assisted in the writing and critical review of the manuscript. He satisfies ICMJE criteria for authorship. He enrolled a significant number of patients to this clinical trial and was an important member of the research team. On behalf of my colleagues, I would like to re-designate the authorship of this manuscript as follows (changes in bold): Ronan T. Swords MD, PhD, FRCPI, FRCPatha, Peter L. Greenberg, MDb, Andrew H. Wei, MBBS, PhDc, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPathd, Anjali S. Advani, MDe, Mark S Hertzberg, MBBS, PhD, FRACP, FRCPAf, Brian A. Jonas MD, PhDg, Ian D Lewis, MBBS, PhDh, Gabriel Rivera, MDb, Dita Gratzinger, MD, PhDb, Alice C. Fan, MDb, Dean W. Felsher, MD, PhDb, Jorge E. Cortes, MDi, Justin M. Watts, MDa, Geoff T. Yarranton, PhDj, Jackie M. Walling, MB, ChB, PhDj, and Jeffrey E. Lancet, MDk Authorship affiliations are as follows (changes in bold): aLeukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States (corresponding author). bStanford Cancer Institute, Stanford, CA, United States cThe Alfred Hospital and Monash University, Melbourne, Australia dThe Royal Brisbane and Women's Hospital, Brisbane, Australia eCleveland Clinic, Cleveland, OH, United States fWestmead Hospital, Westmead, Australia gDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, United States hThe Royal Adelaide Hospital, Adelaide, Australia iThe University of Texas MD Anderson Cancer Center, Houston, TX, United States jKaloBios Pharmaceuticals, Inc., South San Francisco, CA, United States kH Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States Please issue this corrigendum in the next issue of the journal. The authors would like to sincerely apologise for any inconvenience caused.

Original languageEnglish
Number of pages1
JournalLeukemia Research
Volume59
DOIs
Publication statusPublished - 1 Aug 2017

Cite this

Swords, Ronan T. ; Greenberg, Peter L. ; Wei, Andrew H. ; Durrant, Simon ; Advani, Anjali S. ; Hertzberg, Mark S. ; Lewis, Ian D ; Rivera, Gabriel ; Gratzinger, Dita ; Fan, Alice C. ; Felsher, Dean W. ; Cortes, Jorge E. ; Watts, Justin M. ; Yarranton, Geoff T. ; Walling, Jackie M. ; Lancet, Jeffrey E. / Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies : Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012). In: Leukemia Research. 2017 ; Vol. 59.
@article{53dca5c75b854d7393324527a705cb38,
title = "Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)",
abstract = "The authors regret to inform, that a key author (Dr. Brian A. Jonas MD PhD), was inadvertently omitted form the authorship of this manuscript at the time of publication. Dr. Jonas was a key contributor to the design, conception and data analysis of this work. He assisted in the writing and critical review of the manuscript. He satisfies ICMJE criteria for authorship. He enrolled a significant number of patients to this clinical trial and was an important member of the research team. On behalf of my colleagues, I would like to re-designate the authorship of this manuscript as follows (changes in bold): Ronan T. Swords MD, PhD, FRCPI, FRCPatha, Peter L. Greenberg, MDb, Andrew H. Wei, MBBS, PhDc, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPathd, Anjali S. Advani, MDe, Mark S Hertzberg, MBBS, PhD, FRACP, FRCPAf, Brian A. Jonas MD, PhDg, Ian D Lewis, MBBS, PhDh, Gabriel Rivera, MDb, Dita Gratzinger, MD, PhDb, Alice C. Fan, MDb, Dean W. Felsher, MD, PhDb, Jorge E. Cortes, MDi, Justin M. Watts, MDa, Geoff T. Yarranton, PhDj, Jackie M. Walling, MB, ChB, PhDj, and Jeffrey E. Lancet, MDk Authorship affiliations are as follows (changes in bold): aLeukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States (corresponding author). bStanford Cancer Institute, Stanford, CA, United States cThe Alfred Hospital and Monash University, Melbourne, Australia dThe Royal Brisbane and Women's Hospital, Brisbane, Australia eCleveland Clinic, Cleveland, OH, United States fWestmead Hospital, Westmead, Australia gDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, United States hThe Royal Adelaide Hospital, Adelaide, Australia iThe University of Texas MD Anderson Cancer Center, Houston, TX, United States jKaloBios Pharmaceuticals, Inc., South San Francisco, CA, United States kH Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States Please issue this corrigendum in the next issue of the journal. The authors would like to sincerely apologise for any inconvenience caused.",
author = "Swords, {Ronan T.} and Greenberg, {Peter L.} and Wei, {Andrew H.} and Simon Durrant and Advani, {Anjali S.} and Hertzberg, {Mark S.} and Lewis, {Ian D} and Gabriel Rivera and Dita Gratzinger and Fan, {Alice C.} and Felsher, {Dean W.} and Cortes, {Jorge E.} and Watts, {Justin M.} and Yarranton, {Geoff T.} and Walling, {Jackie M.} and Lancet, {Jeffrey E.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.leukres.2017.02.007",
language = "English",
volume = "59",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Pergamon",

}

Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies : Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012). / Swords, Ronan T.; Greenberg, Peter L.; Wei, Andrew H.; Durrant, Simon; Advani, Anjali S.; Hertzberg, Mark S.; Lewis, Ian D; Rivera, Gabriel; Gratzinger, Dita; Fan, Alice C.; Felsher, Dean W.; Cortes, Jorge E.; Watts, Justin M.; Yarranton, Geoff T.; Walling, Jackie M.; Lancet, Jeffrey E.

In: Leukemia Research, Vol. 59, 01.08.2017.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies

T2 - Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)

AU - Swords, Ronan T.

AU - Greenberg, Peter L.

AU - Wei, Andrew H.

AU - Durrant, Simon

AU - Advani, Anjali S.

AU - Hertzberg, Mark S.

AU - Lewis, Ian D

AU - Rivera, Gabriel

AU - Gratzinger, Dita

AU - Fan, Alice C.

AU - Felsher, Dean W.

AU - Cortes, Jorge E.

AU - Watts, Justin M.

AU - Yarranton, Geoff T.

AU - Walling, Jackie M.

AU - Lancet, Jeffrey E.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - The authors regret to inform, that a key author (Dr. Brian A. Jonas MD PhD), was inadvertently omitted form the authorship of this manuscript at the time of publication. Dr. Jonas was a key contributor to the design, conception and data analysis of this work. He assisted in the writing and critical review of the manuscript. He satisfies ICMJE criteria for authorship. He enrolled a significant number of patients to this clinical trial and was an important member of the research team. On behalf of my colleagues, I would like to re-designate the authorship of this manuscript as follows (changes in bold): Ronan T. Swords MD, PhD, FRCPI, FRCPatha, Peter L. Greenberg, MDb, Andrew H. Wei, MBBS, PhDc, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPathd, Anjali S. Advani, MDe, Mark S Hertzberg, MBBS, PhD, FRACP, FRCPAf, Brian A. Jonas MD, PhDg, Ian D Lewis, MBBS, PhDh, Gabriel Rivera, MDb, Dita Gratzinger, MD, PhDb, Alice C. Fan, MDb, Dean W. Felsher, MD, PhDb, Jorge E. Cortes, MDi, Justin M. Watts, MDa, Geoff T. Yarranton, PhDj, Jackie M. Walling, MB, ChB, PhDj, and Jeffrey E. Lancet, MDk Authorship affiliations are as follows (changes in bold): aLeukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States (corresponding author). bStanford Cancer Institute, Stanford, CA, United States cThe Alfred Hospital and Monash University, Melbourne, Australia dThe Royal Brisbane and Women's Hospital, Brisbane, Australia eCleveland Clinic, Cleveland, OH, United States fWestmead Hospital, Westmead, Australia gDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, United States hThe Royal Adelaide Hospital, Adelaide, Australia iThe University of Texas MD Anderson Cancer Center, Houston, TX, United States jKaloBios Pharmaceuticals, Inc., South San Francisco, CA, United States kH Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States Please issue this corrigendum in the next issue of the journal. The authors would like to sincerely apologise for any inconvenience caused.

AB - The authors regret to inform, that a key author (Dr. Brian A. Jonas MD PhD), was inadvertently omitted form the authorship of this manuscript at the time of publication. Dr. Jonas was a key contributor to the design, conception and data analysis of this work. He assisted in the writing and critical review of the manuscript. He satisfies ICMJE criteria for authorship. He enrolled a significant number of patients to this clinical trial and was an important member of the research team. On behalf of my colleagues, I would like to re-designate the authorship of this manuscript as follows (changes in bold): Ronan T. Swords MD, PhD, FRCPI, FRCPatha, Peter L. Greenberg, MDb, Andrew H. Wei, MBBS, PhDc, Simon Durrant, MBBS, MRCS, LRCP, FRCP, FRCPathd, Anjali S. Advani, MDe, Mark S Hertzberg, MBBS, PhD, FRACP, FRCPAf, Brian A. Jonas MD, PhDg, Ian D Lewis, MBBS, PhDh, Gabriel Rivera, MDb, Dita Gratzinger, MD, PhDb, Alice C. Fan, MDb, Dean W. Felsher, MD, PhDb, Jorge E. Cortes, MDi, Justin M. Watts, MDa, Geoff T. Yarranton, PhDj, Jackie M. Walling, MB, ChB, PhDj, and Jeffrey E. Lancet, MDk Authorship affiliations are as follows (changes in bold): aLeukemia Program, Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, FL, United States (corresponding author). bStanford Cancer Institute, Stanford, CA, United States cThe Alfred Hospital and Monash University, Melbourne, Australia dThe Royal Brisbane and Women's Hospital, Brisbane, Australia eCleveland Clinic, Cleveland, OH, United States fWestmead Hospital, Westmead, Australia gDepartment of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, UC Davis Comprehensive Cancer Center, United States hThe Royal Adelaide Hospital, Adelaide, Australia iThe University of Texas MD Anderson Cancer Center, Houston, TX, United States jKaloBios Pharmaceuticals, Inc., South San Francisco, CA, United States kH Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States Please issue this corrigendum in the next issue of the journal. The authors would like to sincerely apologise for any inconvenience caused.

UR - http://www.scopus.com/inward/record.url?scp=85020052613&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2017.02.007

DO - 10.1016/j.leukres.2017.02.007

M3 - Comment / Debate

VL - 59

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

ER -